Contraception
Volume 75, Issue 6 , Pages 407-419 , June 2007

Biomarkers of semen in the vagina: applications in clinical trials of contraception and prevention of sexually transmitted pathogens including HIV

  • Christine K. Mauck

      Affiliations

    • CONRAD, Eastern Virginia Medical School (EVMS), Arlington, VA 22209, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 703 276 3912; fax: +1 703 524 4770.
    • ,
  • Gustavo F. Doncel

      Affiliations

    • CONRAD, EVMS, Norfolk, VA 23507, USA
    • ,
  • Biomarkers of Semen Exposure Clinical Working Group

Received 16 August 2006 ,Revised 13 February 2007 ,Accepted 23 February 2007.

References 

  1. Wang P, Meijer J, Guengerich FP. Purification of human liver cytosolic epoxide hydrolase and comparison to the microsomal enzyme. Biochemistry. 1982;21:5769–5776
  2. Sensabaugh GF. The quantitative acid phosphatase test. A statistical analysis of the endogenous and postcoital acid phosphatase levels in the vagina. J Forensic Sci. 1979;24:346–365
  3. Wang MC. VLMGCT. Tissue specific and tumor specific antigens in human prostate. Fed Proc. 1977;36:1254
  4. Lilja H. Structure, function, and regulation of the enzyme activity of prostate-specific antigen. World J Urol. 1993;11:188–191
  5. Malm J, Hellman J, Hogg P, Lilja H. Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn(2+), a tight-binding inhibitor. Prostate. 2000;45:132–139
  6. Filella X, Molina R, Alcover J, Carretero P, Ballesta AM. Detection of nonprostatic PSA in serum and nonserum samples from women. Int J Cancer. 1996;68:424–427
  7. Schmidt S, Franke M, Lehmann J, Loch T, Stockle M, Weichert-Jacobsen K. Prostate-specific antigen in female urine: a prospective study involving 217 women. Urology. 2001;57:717–720
  8. Negri C, Tosi F, Dorizzi R, et al. Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: evidence that serum PSA is a marker of androgen action in women. J Clin Endocrinol Metab. 2000;85:81–84
  9. Obiezu CV, Scorilas A, Magklara A, et al. Prostate-specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2001;86:1558–1561
  10. Steiner MJ, Feldblum PJ, Padian N. Invited commentary: condom effectiveness — will prostate-specific antigen shed new light on this perplexing problem?. Am J Epidemiol. 2003;157:298–300[discussion 301-2]
  11. Walsh TL, Frezieres RG, Peacock K, et al. Use of prostate-specific antigen (PSA) to measure semen exposure resulting from male condom failures: implications for contraceptive efficacy and the prevention of sexually transmitted disease. Contraception. 2003;67:139–150
  12. Lawson ML, Macaluso M, Bloom A, Hortin G, Hammond KR, Blackwell R. Objective biomarkers of condom failure. Sex Transm Dis. 1998;25:427–432
  13. Macaluso M, Lawson L, Akers R, et al. Prostate-specific antigen in vaginal fluid as a biologic biomarker of condom failure. Contraception. 1999;59:195–201
  14. Nam JM, Thaxton CS, Mirkin CA. Nanoparticle-based bio-bar codes for the ultrasensitive detection of proteins. Science. 2003;301:1884–1886
  15. Lilja H, Abrahamsson PA, Lundwall A. Semenogelin, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa. J Biol Chem. 1989;264:1894–1900
  16. Malm J, Hellman J, Magnusson H, Laurell CB, Lilja H. Isolation and characterization of the major gel proteins in human semen, semenogelin I and semenogelin II. Eur J Biochem. 1996;238:48–53
  17. Lundwall A, Bjartell A, Olsson AY, Malm J. Semenogelin I and II, the predominant human seminal plasma proteins, are also expressed in non-genital tissues. Mol Hum Reprod. 2002;8:805–810
  18. Herr JC, Summers TA, McGee RS, Sutherland WM, Sigman M, Evans RJ. Characterization of a monoclonal antibody to a conserved epitope on human seminal vesicle-specific peptides: a novel probe/marker system for semen identification. Biol Reprod. 1986;35(3):773–784
  19. Haimovici F, Anderson DJ. Detection of semen in cervicovaginal secretions. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8:236–238
  20. Pang BCM, Cheung BKK. Identification of human semenogelin in membrane strip test as an alternative method for the detection of semen. Foren Sci Internat. 2006;[doi:10.1016/j.forsciint.2006.07.021. Accessed 8/16/06]
  21. Henneberry MO, Engel G, Grayhack JT. Acid phosphatase. Urol Clin North Am. 1979;6:629–641
  22. Archer DF, Mauck CK, Viniegra-Sibal A, et al. Lea's Shield: a phase I postcoital study of a new contraceptive barrier device. Contraception. 1995;52:167–173
  23. Mauck C, Glover LH, Miller E, et al. Lea's Shield: a study of the safety and efficacy of a new vaginal barrier contraceptive used with and without spermicide. Contraception. 1996;53:329–335
  24. Mauck CK, Baker JM, Barr SP, et al. A phase I study of FemCap used with and without spermicide. Postcoital testing. Contraception. 1997;56:111–115
  25. Mauck C, Callahan M, Weiner DH, et al. A comparative study of the safety and efficacy of FemCap, a new vaginal barrier contraceptive, and the Ortho All-Flex diaphragm. The FemCap Investigators' Group. Contraception. 1999;60:71–80
  26. World Health Organization . In: WHO laboratory manual for the examination of human semen and sperm–cervical mucus interaction. 3rd ed. Cambridge University Press; 1999;p. 35
  27. Zenilman JM, Yuenger J, Galai N, Turner CF, Rogers SM. Polymerase chain reaction detection of Y chromosome sequences in vaginal fluid: preliminary studies of a potential biomarker for sexual behavior. Sex Transm Dis. 2005;32:90–94
  28. Pfitzinger H, Ludes B, Mangin P. Sex determination of forensic samples: co-amplification and simultaneous detection of a Y-specific and an X-specific DNA sequence. Int J Legal Med. 1993;105:213–216
  29. Reynolds R, Varlaro J. Gender determination of forensic samples using PCR amplification of ZFX/ZFY gene sequences. J Forensic Sci. 1996;41:279–286
  30. Bauer M, Patzelt D. Protamine mRNA as molecular marker for spermatozoa in semen stains. Int J Legal Med. 2003;117:175–179
  31. Kerr LE. Sperm antigens and immunocontraception. Reprod Fertil Dev. 1995;7:825–830
  32. Diekman AB, Herr JC. Sperm antigens and their use in the development of an immunocontraceptive. Am J Reprod Immunol. 1997;37:111–117
  33. Naz RK. Vaccine for contraception targeting sperm. Immunol Rev. 1999;171:193–202
  34. Naaby-Hansen S, Mandal A, Wolkowicz MJ, et al. CABYR, a novel calcium-binding tyrosine phosphorylation-regulated fibrous sheath protein involved in capacitation. Dev Biol. 2002;242:236–254
  35. Millan JL, Driscoll CE, Le Van KM, Goldberg E. Epitopes of human testis-specific lactate dehydrogenase deduced from a cDNA sequence. Proc Natl Acad Sci U S A. 1987;84:5311–5315
  36. Walsh TL, Frezieres RG, Nelson AL, Wraxall BG, Clark VA. Evaluation of prostate-specific antigen as a quantifiable indicator of condom failure in clinical trials. Contraception. 1999;60:289–298
  37. Walsh TL, Frezieres RG, Peacock K, et al. Effectiveness of the male latex condom: combined results for three popular condom brands used as controls in randomized clinical trials. Contraception. 2004;70:407–413
  38. Macaluso M, Lawson ML, Hortin G, Duerr A, Hammond KR, Blackwell R, et al. Efficacy of the female condom as a barrier to semen during intercourse. Am J Epidemiol. 2003;157:289–297
  39. Galvao LW, Oliveira LC, Diaz J, et al. Effectiveness of female and male condoms in preventing exposure to semen during vaginal intercourse: a randomized trial. Contraception. 2005;71:130–136
  40. Moench TR, Chipato T, Padian NS. Preventing disease by protecting the cervix: the unexplored promise of internal vaginal barrier devices. AIDS. 2001;15:1595–1602
  41. Jadack RA, Yuenger J, Ghanem KG, Zenilman J. Polymerase chain reaction detection of Y-chromosome sequences in vaginal fluid of women accessing a sexually transmitted disease clinic. Sex Transm Dis. 2006;33:22–25
  42. Chomont N, Gresenguet G, Levy M, et al. Detection of Y chromosome DNA as evidence of semen in cervicovaginal secretions of sexually active women. Clin Diagn Lab Immunol. 2001;8:955–958
  43. van de Wijgert J, Altini L, Jones H, de Kock A, Young T, Williamson AL, et al. Two methods of self-sampling compared to clinician sampling to detect reproductive tract infections in Gugulethu South Africa. Sex Transm Dis. 2006;33:516–523
  44. Godley MJ. Quantitation of vaginal discharge in healthy volunteers. Br J Obstet Gynaecol. 1985;92:739–742

☆ There was no funding since this paper is a review of the literature.

PII: S0010-7824(07)00116-3

doi: 10.1016/j.contraception.2007.02.007

Contraception
Volume 75, Issue 6 , Pages 407-419 , June 2007

Article Tools

* Image Usage & Resolution